Compare EEX & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEX | GHRS |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | Ireland |
| Employees | 821 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 890.6M | 947.2M |
| IPO Year | N/A | 2021 |
| Metric | EEX | GHRS |
|---|---|---|
| Price | $4.98 | $24.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $7.70 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 714.2K | 190.3K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.49 | N/A |
| Revenue Next Year | $6.81 | N/A |
| P/E Ratio | $236.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.32 | $10.96 |
| 52 Week High | $5.45 | $24.66 |
| Indicator | EEX | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 57.33 | 66.60 |
| Support Level | $4.81 | $12.65 |
| Resistance Level | $5.09 | $24.66 |
| Average True Range (ATR) | 0.03 | 1.55 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 13.65 | 92.71 |
Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States, with operations in the United Kingdom (U.K.), France, and other markets. The company is engaged in three complementary business lines: Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division provides B2B e-commerce and digital merchandising solutions to manufacturers and retailers. Emerald's key revenue is derived from the Connections business, its only reportable segment.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.